.Pharmacolibrary.Drugs.R_RespiratorySystem.R06A_AntihistaminesForSystemicUse.R06AX28_Rupatadine.Rupatadine

Information

Rupatadine is a second-generation antihistamine and platelet-activating factor (PAF) antagonist used primarily for the symptomatic treatment of allergic rhinitis and urticaria. It is an orally active, non-sedating agent that is approved and available in many countries for these indications.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, after a single oral dose administration.

References

1. Santamaria, E, et al., & Valle, M (2021). Rupatadine Oral Solution Titration by Body Weight in Paediatric Patients Suffering from Allergic Rhinitis: A Population Pharmacokinetic Study. Clinical pharmacology : advances and applications 13 115–122. DOI:10.2147/CPAA.S312911 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34135645

2. Xiong, Y, et al., & Liu, M (2016). CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. European journal of drug metabolism and pharmacokinetics 41(2) 117–124. DOI:10.1007/s13318-014-0236-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25427746

3. Peña, J, et al., & Merlos, M (2008). Antihistaminic effects of rupatadine and PKPD modelling. European journal of drug metabolism and pharmacokinetics 33(2) 107–116. DOI:10.1007/BF03191027 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18777946

Revisions

• 06/2025 initial generated model